Recent Insider Transactions • Mar 15
Co-Founder & Executive Chairperson recently bought €268k worth of stock On the 12th of March, James Mellon bought around 3m shares on-market at roughly €0.081 per share. This transaction amounted to 34% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €432k worth in shares. Recent Insider Transactions • Feb 26
Co-Founder & Executive Chairperson recently bought €76k worth of stock On the 25th of February, James Mellon bought around 990k shares on-market at roughly €0.076 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €118k worth in shares. Tillkännagivande • Dec 30
Agronomics Limited, Annual General Meeting, Feb 13, 2026 Agronomics Limited, Annual General Meeting, Feb 13, 2026. Location: the sanderson suite, claremont hotel, loch promenade, douglas im1 2lx Isle of Man Buy Or Sell Opportunity • Dec 05
Now 24% undervalued after recent price drop Over the last 90 days, the stock has fallen 13% to €0.067. The fair value is estimated to be €0.088, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 61% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Nov 19
Now 22% undervalued The stock has been flat over the last 90 days, currently trading at €0.074. The fair value is estimated to be €0.095, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 61% over the last 3 years. Meanwhile, the company became loss making. New Risk • Aug 09
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €85.1m (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 8.1% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€85.1m market cap, or US$99.1m). New Risk • Mar 15
New major risk - Revenue and earnings growth Earnings have declined by 8.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 8.1% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€82.2m market cap, or US$89.4m). Recent Insider Transactions • Feb 07
Co-Founder & Executive Chairperson recently bought €59k worth of stock On the 4th of February, James Mellon bought around 1m shares on-market at roughly €0.046 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €234k worth in shares. Tillkännagivande • Dec 28
Agronomics Limited, Annual General Meeting, Feb 07, 2025 Agronomics Limited, Annual General Meeting, Feb 07, 2025. Location: the sanderson suite, claremont hotel, loch promenade, im1 2lx, douglas Isle of Man New Risk • Dec 25
New major risk - Revenue size The company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€46.6m market cap, or US$48.4m). Recent Insider Transactions • Oct 15
Co-Founder & Executive Chairperson recently bought €115k worth of stock On the 7th of October, James Mellon bought around 2m shares on-market at roughly €0.058 per share. This transaction amounted to 43% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €174k worth in shares. New Risk • Sep 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Profit margins are more than 30% lower than last year (31% net profit margin). Market cap is less than US$100m (€68.4m market cap, or US$75.6m). New Risk • May 29
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €90.2m (US$97.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Profit margins are more than 30% lower than last year (31% net profit margin). Market cap is less than US$100m (€90.2m market cap, or US$97.5m). New Risk • Apr 15
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €88.7m (US$94.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Profit margins are more than 30% lower than last year (31% net profit margin). Market cap is less than US$100m (€88.7m market cap, or US$94.4m). Tillkännagivande • Mar 15
Umami Meats Pte. Ltd. acquired Shiok Meats Pte. Ltd. from Agronomics Limited (AIM:ANIC) and others. Umami Meats Pte. Ltd. acquired Shiok Meats Pte. Ltd. from Agronomics Limited (AIM:ANIC) and others on March 13, 2024. Umami acquired Shiok Meats in share-for-share transaction. As a result of this transaction, Agronomics now holds an equity ownership of 0.71% in UMAMI Bioworks on a fully diluted basis. Subject to audit, this position will be carried forward at a book value of £0.378 million. James Biddle and Roland Cornish of Beaumont Cornish Limited acted as Financial advisor in transaction.
Umami Meats Pte. Ltd. completed the acquisition of Shiok Meats Pte. Ltd. from Agronomics Limited (AIM:ANIC) and others on March 13, 2024 Tillkännagivande • Jan 18
Agronomics Limited Announces IsraFirst Regulatory Approval for Cultivated Beef Agronomics Ltd. announced that the Israeli Ministry of Health (IMOH) has granted regulatory approval for the world's first commercial sale of cultivated beef. Agronomics would like to congratulate Aleph Farms on becoming the first company in the world to gain regulatory approval for its cultivated beef product after the IMOH issued a 'no questions' letter, which allows the company to commercialise its products in Israel. Aleph Farms has also filed for regulatory approval in Singapore, Switzerland, the UK and the US, and is advancing its applications in other markets. Agronomics is aware of multiple companies, including those within its portfolio, that are expecting regulatory approval for cultivated meat and seafood products across several markets. Meanwhile, Vow Food is in the middle of a consultation process after its cultured quail was cleared as safe to eat by Food Standards Australia and New Zealand in December 2023. These announcements follow Upside Foods and Good Meat, which received regulatory approval for their cultivated chicken products in the US last year. New Risk • Dec 27
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 75% Last year net profit margin: 130% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Profit margins are more than 30% lower than last year (75% net profit margin). Tillkännagivande • Dec 27
Agronomics Limited, Annual General Meeting, Feb 08, 2024 Agronomics Limited, Annual General Meeting, Feb 08, 2024, at 10:00 Coordinated Universal Time. Location: Sanderson Suite, Claremont Hotel, Loch Promenade Douglas Isle of Man Tillkännagivande • Dec 14
Agronomics Limited appoints Jim Mellon as Executive Chairperson of the Board of Directors, 14 December 2023 Agronomics Limited announced that it has appointed Jim Mellon as Executive Chairperson of the Board of Directors, effective 14 December 2023. Jim Mellon, formerly an Executive Director, succeeds Richard Reed in the role of Chair, with Richard Reed continuing to serve as an Independent Non-Executive Director of the Board. Tillkännagivande • Sep 23
Agronomics Limited (AIM:ANIC) announces an Equity Buyback for £3 million worth of its shares. Agronomics Limited (AIM:ANIC) announces a share repurchase program. Under the program, the company will repurchase up to £3 million worth of its shares. The maximum price to be paid for repurchase is the higher of the price of the last independent trade and the highest current independent purchase bid on the trading venue where the purchase is carried out and no share shall be bought back by the Company at a price per share higher than 75% of the last reported NAV Per Share published in the Company's most recent Quarterly NAV Statement. The purpose of the program is to reduce the share capital of the company. The repurchased shares will be cancelled unless used to cover obligations under share-based remuneration arrangements. The program will be valid till March 29, 2024. As of September 22, 2023, the company had 993,153,870 issued shares. New Risk • Aug 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Recent Insider Transactions • May 12
Executive Director recently bought €52k worth of stock On the 5th of May, James Mellon bought around 392k shares on-market at roughly €0.13 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €79k. Insiders have collectively bought €137k more in shares than they have sold in the last 12 months. Recent Insider Transactions • Mar 29
Executive Director recently bought €79k worth of stock On the 27th of March, James Mellon bought around 666k shares on-market at roughly €0.12 per share. This transaction amounted to 50% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €85k more in shares than they have sold in the last 12 months. Tillkännagivande • Dec 21
Agronomics Limited, Annual General Meeting, Feb 02, 2023 Agronomics Limited, Annual General Meeting, Feb 02, 2023, at 10:00 Coordinated Universal Time. Location: Sanderson Suite, Claremont Hotel Loch Promenade Douglas Isle of Man Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director David Giampaolo was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Jun 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director David Giampaolo was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director David Giampaolo was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
